- Home
- CELC vs INSW Comparison
CELC vs INSW Comparison
Compare CELC & INSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- INSW
- Stock Information
- Founded
- CELC 2011
- INSW 1999
- Country
- CELC United States
- INSW United States
- Employees
- CELC N/A
- INSW N/A
- Industry
- CELC Medical Specialities
- INSW Semiconductors
- Sector
- CELC Health Care
- INSW Technology
- Exchange
- CELC Nasdaq
- INSW Nasdaq
- Market Cap
- CELC 2.3B
- INSW 2.3B
- IPO Year
- CELC 2017
- INSW N/A
- Fundamental
- Price
- CELC $50.51
- INSW $47.08
- Analyst Decision
- CELC Strong Buy
- INSW Buy
- Analyst Count
- CELC 6
- INSW 2
- Target Price
- CELC $63.00
- INSW $52.00
- AVG Volume (30 Days)
- CELC 1.0M
- INSW 524.7K
- Earning Date
- CELC 11-13-2025
- INSW 11-06-2025
- Dividend Yield
- CELC N/A
- INSW 6.94%
- EPS Growth
- CELC N/A
- INSW N/A
- EPS
- CELC N/A
- INSW 4.81
- Revenue
- CELC N/A
- INSW $798,838,000.00
- Revenue This Year
- CELC N/A
- INSW N/A
- Revenue Next Year
- CELC N/A
- INSW $4.49
- P/E Ratio
- CELC N/A
- INSW $9.79
- Revenue Growth
- CELC N/A
- INSW N/A
- 52 Week Low
- CELC $7.58
- INSW $27.20
- 52 Week High
- CELC $63.06
- INSW $54.84
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- INSW 54.66
- Support Level
- CELC $44.42
- INSW $45.06
- Resistance Level
- CELC $52.76
- INSW $47.71
- Average True Range (ATR)
- CELC 3.10
- INSW 1.03
- MACD
- CELC -1.11
- INSW -0.37
- Stochastic Oscillator
- CELC 51.39
- INSW 47.75
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.